CIPN often occurs in cancer treatment with platinum agents, a number of antimitotic drugs and bortezomib. These neurotoxic agents target the nervous system at different sites, including the dorsal root ganglions, and the microtubules, ion channels and blood vessels of peripheral axons.
Symptoms are dose-dependent, and mostly sensory (e.g. pain, loss of sensibility) but they can also manifest as motor weakness or autonomic dysfunction.
Damage of small fibers causes pain, hyperesthesia and loss of pain and temperature senses, while injury to large fibers produces loss of vibration sense, loss of proprioception and muscle weakness. There is no known treatment, and CIPN can have a significantly negative long-term effect on daily activities and quality of life in cancer survivors.